Search
for
Sort by
Research 31–60 of 1000+
- Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies
- Reversal of Alopecia Universalis by Tofacitinib: A Case Report
- Haff disease associated with the ingestion of the freshwater fish Mylossoma duriventre (pacu-manteiga)
- Suspected upadacitinib-associated drug hypersensitivity mimicking disease exacerbation in ulcerative colitis
- Farmácia Padrão da Légua, Custóias e nos Serviços Farmacêuticos da Klinicka Bolnica Dubrava, Croácia
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- Evidence for the off-label use of tofacitinib in alopecia areata
- Current Trends and Emerging Paradigms in the Treatment of Alopecia Areata
- Elevated Circulation Levels of an Antiangiogenic SERPIN in Patients with Diabetic Microvascular Complications Impair Wound Healing through Suppression of Wnt Signaling
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis
- Safety assessment of cyclin-dependent kinase 4/6 inhibitors and comparison of time to adverse events
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- Common questions and misconceptions about creatine supplementation: what does the scientific evidence really show?
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- A review of Janus kinase inhibitor use in scarring alopecia
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Part II. Common questions and misconceptions about creatine supplementation: what does the scientific evidence really show?
- Efficacy and safety of omeprazole for severe gastroesophageal reflux in children
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- Biologics in the management of childhood atopic dermatitis
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Alopecia areata: current concepts
- An Updated in the Management of Alopecia Areata
- Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges – A Narrative Review
- Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series
- Baricitinib for the Treatment of Alopecia Areata
- Ritlecitinib for the Management of Alopecia Areata: A Narrative Review of Real-World Evidence and Selected Post Hoc Analyses
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- The JAK/STAT signaling pathway: from bench to clinic